GlaxoSmithKline ((GSK)), GlaxoSmithKline plc (UK) ((GB:GSK)) announced an update on their ongoing clinical study.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
GlaxoSmithKline (GSK) is conducting a Phase 3 clinical study titled A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease. The study aims to evaluate the effectiveness and safety of belimumab, administered subcutaneously, in stabilizing or improving lung function in patients with interstitial lung disease (ILD) linked to connective tissue diseases (CTD). This condition significantly impacts quality of life and is a leading cause of death among affected individuals.
The intervention involves belimumab, a biological treatment, given alongside standard therapy to test its potential benefits in managing ILD symptoms. A placebo group will also receive standard therapy for comparison.
The study is designed as a randomized, double-blind, placebo-controlled trial with a parallel group model. It aims to treat participants while ensuring unbiased results through quadruple masking, involving participants, care providers, investigators, and outcomes assessors.
The study began on September 11, 2024, with its primary completion and estimated overall completion dates yet to be announced. The most recent update was submitted on June 23, 2025, indicating ongoing progress.
This study could influence GSK’s stock performance positively if belimumab proves effective, potentially boosting investor confidence. The outcome may also impact the competitive landscape in the treatment of ILD associated with CTD.
The study is currently recruiting, with further details available on the ClinicalTrials portal.